Positive IDMC recommendation based on an interim analysis of the masitinib phase 3 study in first-line treatment of castrate-resistant prostate cancer
19/06/2018 – AB Science expects study to be completed in 2019.
Update on EU marketing authorization application for masitinib in the treatment of amyotrophic lateral sclerosis
28/05/2018 – AB Science is evaluating the possibility to resubmit the application based on the final results from study AB10015.
Governance
BOARD OF DIRECTORS The Board of Directors determines the Company’s orientations and oversees their implementation. It deals with all matters concerning the smooth running of the Company and, in its deliberations, matters which concern them. In this context, the Council: Deliberates on the strategy of the Company and the operations there under Appoints corporate…
General Meeting preparatory documents
Bulletin des annonces légales obligatoires – Avis de convocation AGM du 31 Aout 2020 Texte des résolutions AGM du 31 Aout 2020 Formulaire de vote par correspondance AGM du 31 Aout 2020 Demande d’envoi de documents AGM du 31 Aout 2020 Information mensuelle relative au nombre total de droits de vote et d’actions AGM du…
Other information
Gender equality index 2019 Gender equality index
Masivet
Mast cell tumours (MCTs) are the most common cutaneous malignancies in dogs. Masivet® is an effective, well-tolerated and proven treatment for dog MCT and was the first tyrosine kinase inhibitor registered in veterinary oncology when it was approved by the European Medicine Agency in 2008. AB Science celebrated in 2018 the 10th anniversary of the…
Message from the CEO
“AB Science was founded in 2001 by a team of scientists in order to develop new drugs targeting indications with unmet medical needs, in the field of cancers, chronic inflammatory diseases and neurological degenerative disorders. In human medicine, our masitinib pipeline is well advanced with several phase 3 studies in oncology and non-oncology diseases and…
Masitinib General overview
Masitinib, AB Science main compound, is a selective tyrosine kinase inhibitor which is currently developed in three therapeutic areas: neurology, inflammatory diseases and oncology. As of today, masitinib is mainly developed in the following indications: amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer disease, mastocytosis, severe asthma, prostate cancer and pancreatic cancer. Masitinib pipeline is well advanced with…
Masitinib in Neurology
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative, life-threatening disease characterized by progressive muscular paralysis reflecting degeneration of motor neurons. While the average survival time is 3 years, about 10 percent of people with ALS will survive 10 years. Preclinical studies show that masitinib is capable of exerting neuroprotection in both the central and peripheral nervous…
Overview
AB Science is developing its lead compound masitinib in veterinary medicine. Since 2008 in Europe and since 2010 in the USA, masitinib is registered in a canine cancer called mast cell tumor, the most common cutaneous cancer in dogs. The drug is marketed by AB Science under the brand Masivet® in Europe and Kinavet in the…